Stockreport

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week [Yahoo! Finance]

Maze Therapeutics, Inc.  (MAZE) 
PDF clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced seven presentatio [Read more]